Enigma Genomics utilizes next-generation sequencing technologies and artificial intelligence to decode individual genomes, providing personalized genetic insights that inform health decisions. The platform enables users to access and control their genetic data for life, facilitating proactive disease prevention and tailored medical treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Individuals often lack direct access to their comprehensive genetic information, hindering proactive health management and personalized treatment plans. Traditional genetic testing can be limited in scope, preventing individuals from fully understanding their genetic predispositions and risks over their lifetime.
Solution
Enigma Genomics offers direct-to-consumer access to comprehensive genome sequencing and AI-powered analysis, empowering individuals to understand their genetic predispositions and manage their health proactively. By providing lifetime access to genetic data, individuals can request updated analyses and insights as new research emerges, without needing to provide additional samples. The platform emphasizes data ownership and control, ensuring that individuals maintain exclusive access to their genetic information and decide how it is used and shared. Enigma Genomics employs advanced security measures, including data encryption and compliance with international standards, to protect the privacy and confidentiality of user data.
Target Audience
The primary target audience includes individuals seeking proactive health management, personalized medicine, and a deeper understanding of their genetic predispositions, as well as families interested in carrier screening for inherited diseases.
Features
- Whole-genome sequencing using next-generation sequencing technologies
- AI-powered interpretation of genetic data to identify potential health risks and predispositions
- Lifetime access to genetic data with periodic updates and re-analysis options
- Secure data storage and encryption to protect user privacy
- User-controlled data sharing options, ensuring individual consent for any third-party access
- Compliance with HIPAA, ISO/IEC 27001:2013, 27018, and 27701 standards for data security
- Saliva-based sample collection, eliminating the need for blood draws